Azacitidine plus ruxolitinib for higher-risk MDS/MPN
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests whether combining azacitidine and ruxolitinib can better control higher-risk bone marrow diseases (MDS/MPN, including CMML). It may help patients who are not good candidates for a stem cell transplant and who can safely take these medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a higher-risk diagnosis such as CMML, or another MDS/MPN type like aCML or MDS/MPN-U (based on specific risk scores).
- Your blood counts must be: neutrophils at least 2.0 × 10^9/L and platelets at least 25 × 10^9/L.
- You’re not a good candidate for a stem cell transplant (based on local standards).
- Your bone marrow blasts must be at least 5% if you have MDS/MPN types other than CMML.
- Your heart and organ tests must be safe (for example, heart pump strength on ultrasound at least 50%, and kidney/liver tests not too high).
- You must be able to sign consent and have a good enough daily function level (ECOG 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a new treatment plan (decitabine-related medicine with other targeted drugs, depending on the arm) for adults with MDS/MPN overlap syndromes. It aims to improve control of the disease by targeting the abnormal bone marrow cells. Because it’s Phase 1/2, the main goal is to find safe dosing and see whether it helps responses.
This trial tests whether adding donated cord blood stem cells to azacitidine can improve outcomes for people with advanced MDS, CMML-2, or a certain type of AML. It may help by giving the treatment a stronger chance to control abnormal blood-forming cells.
This trial tests a combination of two drugs—a Bcl-2 inhibitor (a type of protein blocker) and azacitidine (a chemotherapy drug)—to treat mixed phenotype acute leukemia (MPAL), a rare blood cancer. The goal is to see if this combination works better than standard treatments for people newly diagnosed with this disease.
This early-phase study tests a combination of ruxolitinib with venetoclax, with or without azacitidine, for adults whose acute myeloid leukemia (AML) has come back or does not respond to treatment. It may help by stopping cancer cells from growing and improving blood counts, with the exact plan guided by the study arm you’re assigned to.
This trial compares two MDS treatments: a combination of two medicines (azacitidine plus luspatercept) versus azacitidine alone. It is for people with high-risk MDS who have not been treated yet.
This early-phase study tests whether combining two “epigenetic” medicines—azacitidine and decitabine—can improve outcomes for certain bone marrow cancers. It may help if you have a type of myelodysplastic syndrome (MDS) or MDS/MPN overlap that is expected to be sensitive to these medicines.
Hear when a new MDS/MPN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.